CRVS research · 13F holders by reporting quarter
Corvus Pharmaceuticals, Inc. (CRVS): 13F holders, 2026Q1
The largest share positions in CRVS that the managers Kresmion follows reported on Form 13F for 2026Q1, as filed. The current quarter, the company's SEC filings and its recent events are on the CRVS research page.
CRVS positions held by the managers we follow (2026Q1)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC FundCUSIP 221015100 · 2026Q1 | $12.7M | 0.01% | +25.8% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 221015100 · 2026Q1 | $7.9M | 0.01% | +276.0% |
| CITADEL ADVISORS LLC FundCUSIP 221015100 · 2026Q1 | $6.5M | 0.00% | n/a |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 221015100 · 2026Q1 | $1.2M | 0.00% | n/a |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.